Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Takeda (Shire),Agalsidase alfa,Fabry disease (a-galactosidase A deficiency),Agalsidase alfa,Options for investment,Community and Hospital,Alimentary Tract and Metabolism
